

UK-Runcorn: pharmaceutical products

OJ S 137/2012 19/07/2012

Contract notice

Supplies

Directive 2004/18/EC

## Section I: Contracting authority

---

### I.1. Name and addresses

Official name: NHS Commercial Medicines Unit

Postal address: Castle View House, East Lane

Town: Runcorn

Postal code: WA7 2AA

Country: United Kingdom

For the attention of: Jayne Douglas

E-mail: [jayne.douglas@cmu.nhs.uk](mailto:jayne.douglas@cmu.nhs.uk)

**Additional information can be obtained from:**

the abovementioned address

**Specifications and additional documents (including documents for competitive dialogue and a dynamic purchasing system) can be obtained from:**

the abovementioned address

**Tenders or requests to participate must be submitted:** the abovementioned address

### I.2. Type of the contracting authority

Ministry or any other national or federal authority, including their regional or local subdivisions

### I.3. Main activity

Health

Other: Public procurement

### I.4. Contract award on behalf of other contracting authorities

The contracting authority is purchasing on behalf of other contracting authorities: yes

## Section II: Object of the contract

---

### II.1. Description

#### II.1.1. Title attributed to the contract by the contracting authority

NHS framework agreement for Cytokine modulator pharmaceuticals for the central pharmacy purchasing group.

#### II.1.2. Type of contract and place of performance or delivery

Supplies

Purchase

Main site or place of performance: All NHS trusts listed in Document 10a of the ITT entitled purchasing points.

NUTS code

#### II.1.3. Information about a framework agreement or a dynamic purchasing system

The procurement involves the establishment of a framework agreement

#### **II.1.4. Information about framework agreement**

##### **Duration of the framework agreement**

Duration in months: 12

#### **II.1.5. Short description of the contract or purchase(s)**

NHS framework agreement for Cytokine modulator pharmaceuticals for the central pharmacy purchasing group. 1.1.2013 to 31.12.2013 with an option to extend for up to a further 12 months.

#### **II.1.6. CPV code(s)**

33600000 Pharmaceutical products

#### **II.1.7. Information about the Government Procurement Agreement (GPA)**

The procurement is covered by the Government Procurement Agreement: yes

#### **II.1.8. Lots**

This contract is divided into lots: no

#### **II.1.9. Information about variants**

Variants will be accepted: yes

### **II.2. Scope of the procurement**

#### **II.2.1. Total quantity or scope**

NHS framework agreement for Cytokine modulator pharmaceuticals for the central pharmacy purchasing group.

#### **II.2.2. Information about options**

Options: yes

Description of options: This framework agreement has the option to be extended for up to a further 12 months.

#### **II.2.3. Information about renewals**

### **II.3. Duration of the contract or time limit for completion**

Duration in months: 12 (from the award of the contract)

## **Section III: Legal, economic, financial and technical information**

---

### **III.1. Conditions related to the contract**

#### **III.1.1. Deposits and guarantees required**

Parent company or other guarantees may be required in certain circumstances. See the invitation to offer for further details.

#### **III.1.2. Main financing conditions and payment arrangements and/or reference to the relevant provisions governing them**

#### **III.1.3. Legal form to be taken by the group of economic operators to whom the contract is to be awarded**

No special legal form is required but, if a contract is awarded to a consortium of economic operators, the members of that consortium may be required to form a legal entity before entering into the framework agreement and may be required to provide parent or directors' guarantees or, if not required to form a legal entity, members of a consortium may be required to accept joint and several liability both to the Contracting Authority under the framework

agreement and to other contracting authorities awarding contracts under the framework agreement.

#### **III.1.4. Contract performance conditions**

The performance of the contract is subject to particular conditions: no

#### **III.2. Conditions for participation**

##### **III.2.1. Suitability to pursue the professional activity, including requirements relating to enrolment on professional or trade registers**

##### **III.2.2. Economic and financial ability**

List and brief description of conditions: Please refer to the award criteria contained in the ITT.

##### **III.2.3. Technical and professional ability**

List and brief description of conditions:

Please refer to the award criteria contained in the ITT.

##### **III.2.4. Information about reserved contracts**

#### **III.3. Conditions specific to services contracts**

##### **III.3.1. Information about a particular profession**

##### **III.3.2. Information about staff responsible for the performance of the contract**

### **Section IV: Procedure**

---

#### **IV.1. Type of procedure**

##### **IV.1.1. Type of procedure**

Open

##### **IV.1.2. Information about the limits on the number of candidates to be invited**

##### **IV.1.3. Information about reduction of the number of solutions or tenders during negotiation or dialogue**

#### **IV.2. Award criteria**

##### **IV.2.1. Award criteria**

The most economically advantageous tender in terms of Price is not the only award criterion and all criteria are stated only in the procurement documents

##### **IV.2.2. Information about electronic auction**

An electronic auction will be used: no

#### **IV.3. Administrative information**

##### **IV.3.1. File reference number attributed by the contracting authority**

CM/PHR/12/5361

##### **IV.3.2. Previous publication concerning this procedure**

no

##### **IV.3.3. Conditions for obtaining specifications and additional documents or descriptive document**

#### **IV.3.4. Time limit for receipt of tenders or requests to participate**

31.8.2012 - 13:00

#### **IV.3.5. Estimated date of dispatch of invitations to tender or to participate to selected candidates**

#### **IV.3.6. Languages in which tenders or requests to participate may be submitted**

English.

#### **IV.3.7. Minimum time frame during which the tenderer must maintain the tender**

#### **IV.3.8. Conditions for opening of tenders**

### **Section VI: Complementary information**

---

#### **VI.1. Information about recurrence**

#### **VI.2. Information about European Union funds**

#### **VI.3. Additional information**

Any supplier may be disqualified who does not respond to the following in the requisite manner:

##### 1) Submission of expression of interest and procurement specific information

This procurement exercise will be conducted on the eTendering portal at [www.cmu.bravosolution.co.uk](http://www.cmu.bravosolution.co.uk). Candidates wishing to be considered for this procurement exercise must register, and provide additional procurement specific information (if requested), through the eTendering portal as follows:

1.1) If not already registered, Candidates should register on the eTendering portal at <https://www.cmu.bravosolution.co.uk> and click the link to register:

- accept the terms and conditions and click continue,
- enter your correct business and user details,
- note the username you chose and click “Save” when complete,
- you will shortly receive an email with your unique password (please keep this secure).

1.2) Once registered, candidates must express interest as follows:

- a. login to the eTendering portal;
- b. select “Response to ITT”;
- c. select “ITTs Open To All Suppliers”;
- d. access listing related to this procurement itt\_29735 - Cental Cytokine Modulators and view details;
- e. click on “Express interest” button at the top of the page.
- f. Once you have expressed interest, the ITT will move to “My ITTs”, where you can download additional documentation (if required), and construct your reply as instructed. You must then publish your reply using the “Publish” button.

1.3) For any support in registering on the portal or submitting your expression of interest please contact the eTendering Help-desk at +44 800 368 4850 or [help@bravosolution.co.uk](mailto:help@bravosolution.co.uk)

##### 2) Entering general supplier information.

To manage and assess supplier information the Contracting Authority requests candidates provide their supplier profile in the NHS Supplier Information Database (sid4health) as follows:

2.1) Candidates must obtain a Dun & Bradstreet (D&B) D-U-N-S® Number to enable registration on sid4health. This normally is provided within 48 hours but may take up to 5 days (turnaround times will vary from country to country), so please ensure this step is completed as soon as possible. The D-U-N-S® number is the standard supplier coding for the NHS and

must be obtained for use in all trading with the NHS. Check to see if your company has a D-U-N-S® Number on the Sid4health registration page.

2.2) Candidates must go to the following web page <http://www.sid4health.nhs.uk/home.action> and select the Register Supplier Organisation on the left of the page. Key in details as shown to search for your D-U-N-S® Number. If you are not on their database click on the link at the bottom of the page to obtain a number from D&B.

2.3) Once registration has been authorised by the sid4health administrator and after receiving logon details, access the Profile Management area and create and validate your sid4health company profile. (Candidates must publish at least one validated profile to make their profile available for buyers to view generally – see the Help page on sid4health within Profile Management for more details).

2.4) Candidates should ensure all the mandatory fields of their sid4health profile are completed. Failure to comply with the completion of all mandatory fields could result in the elimination from the procurement process at this stage. D&B data will be supplied automatically by D&B.

2.5) Once a candidate has ensured that all the required fields are completed and the profile has been validated. They must add the profile to the Request to Participate list ID number T1200\_275 and named itt\_29435 - central cytokine modulator pharmaceuticals. Select 'View all request to participate lists' on the left menu and search/select this list. Select the Join button to the right of the list and then select the validated profile to allocate to this procurement (you may have more than one validated profile as you may have different information held against your profile for different procurements) (Please note the number on the Request To Participate list name should be the same as that generated by the Bravo ITT creation i.e. the itt\_29435 - central cytokine modulator pharmaceuticals. It is easiest to copy and paste this straight from Bravo).

2.6) Where access to sid4health is unavailable, please contact the sid4health Helpdesk at: [helpsid4health@eurodyn.com](mailto:helpsid4health@eurodyn.com)

The framework agreement is for the benefit of other participating NHS bodies (whether acting individually, or on behalf of, or together as members of any consortia) along with any other non-NHS bodies which the participants deem necessary for the delivery of services or goods to NHS bodies, local authorities, other government departments or non-departmental public bodies charged with the delivery of healthcare or health related services.

Contracts awarded under a framework agreement may be awarded either: a) by application of the terms laid down in the framework agreement without reopening competition, or b) where not all the required terms of the proposed contracts are laid down in the framework agreement, by reopening competition between the economic operators which are parties to this framework agreement and which are capable of performing the proposed contract. Reopening of competition will be done in accordance with the procedure set out in Directive 2004/18/EC, Article 32.

Potential suppliers should note that, in accordance with the Government's policies on transparency, the Contracting Authority intends to publish the OJEU, ITT and the text of final contracts / framework agreements, subject to possible redactions at the discretion of the CMU (part of the Department of Health). Further information on transparency can be found at: <http://www.cabinetoffice.gov.uk/resource-library/guidance-transparency>.

## **VI.4. Procedures for review**

### **VI.4.1. Review body**

### **VI.4.2. Review procedure**

**VI.4.3. Service from which information about the review procedure may be obtained**

**VI.5. Date of dispatch of this notice**

16.7.2012